Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study - PubMed

Collaborators, Affiliations

• PMID: 18224343
• DOI: 10.1007/s00467-007-0731-8

Randomized Controlled Trial

Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study

Norishige Yoshikawa et al. Pediatr Nephrol. 2008 May.

Abstract

In two previous randomized controlled trials we showed that treatment of severe childhood immunoglobulin A nephropathy (IgA-N) using prednisolone, azathioprine, heparin-warfarin, and dipyridamole prevented any increase of sclerosed glomeruli and that prednisolone alone did not prevent a further increase of sclerosed glomeruli. Accordingly, the immunosuppressant is considered to be important. Often, however, we were unable to complete azathioprine regimen due to toxicity. Therefore, a different but effective immunosuppressant may be worth trying. Mizoribine, like azathioprine, is an antimetabolite that exerts its immunosuppressant effect by inhibiting lymphocyte proliferation. In this pilot study, we administered mizoribine instead of azathioprine as part of the combination therapy for treating 23 children with severe IgA-N and evaluated the efficacy and safety. Eighteen patients reached the primary endpoint (urine protein/creatinine ratio <0.2) during the 2-year treatment period. The cumulative disappearance rate of proteinuria determined by Kaplan-Meier was 80.4%. Median protein excretion was reduced from 1.19 g/m(2)/day to 0.05 g/m(2)/day (p < 0.0001). After treatment, the median percentage of glomeruli showing sclerosis was unchanged in comparison with that before treatment. No patients required a change of treatment. In conclusion, the efficacy and safety of the mizoribine combination seems to be acceptable for treating children with severe IgA-N.

Similar articles

• Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT.

  Shima Y, Nakanishi K, Kaku Y, Ishikura K, Hataya H, Matsuyama T, Honda M, Sako M, Nozu K, Tanaka R, Iijima K, Yoshikawa N; Japanese Pediatric IgA Nephropathy Treatment Study Group. Shima Y, et al. Pediatr Nephrol. 2018 Nov;33(11):2103-2112. doi: 10.1007/s00467-018-4011-6. Epub 2018 Jul 9. Pediatr Nephrol. 2018. PMID: 29987456 Clinical Trial.

• Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination/prednisolone therapy.

  Shima Y, Nakanishi K, Kamei K, Togawa H, Nozu K, Tanaka R, Sasaki S, Iijima K, Yoshikawa N. Shima Y, et al. Nephrol Dial Transplant. 2011 Jan;26(1):163-9. doi: 10.1093/ndt/gfq387. Epub 2010 Jul 2. Nephrol Dial Transplant. 2011. PMID: 20601366

• Long-term results of a randomized controlled trial in childhood IgA nephropathy.

  Kamei K, Nakanishi K, Ito S, Saito M, Sako M, Ishikura K, Hataya H, Honda M, Iijima K, Yoshikawa N; Japanese Pediatric IgA Nephropathy Treatment Study Group. Kamei K, et al. Clin J Am Soc Nephrol. 2011 Jun;6(6):1301-7. doi: 10.2215/CJN.08630910. Epub 2011 Apr 14. Clin J Am Soc Nephrol. 2011. PMID: 21493743 Free PMC article. Clinical Trial.

• Mizoribine: a new approach in the treatment of renal disease.

  Kawasaki Y. Kawasaki Y. Clin Dev Immunol. 2009;2009:681482. doi: 10.1155/2009/681482. Epub 2009 Dec 13. Clin Dev Immunol. 2009. PMID: 20052390 Free PMC article. Review.

• Steroid therapy in children with IgA nephropathy.

  Cambier A, Boyer O, Deschenes G, Gleeson J, Couderc A, Hogan J, Robert T. Cambier A, et al. Pediatr Nephrol. 2020 Mar;35(3):359-366. doi: 10.1007/s00467-018-4189-7. Epub 2019 Feb 18. Pediatr Nephrol. 2020. PMID: 30778826 Review.

Cited by

• Successful treatment of adult IgA nephropathy with nephrotic-level proteinuria by combination therapy including long-term coadministration of mizoribine.

  Okonogi H, Kawamura T, Matsuo N, Takahashi Y, Yamamoto I, Yoshida H, Koike K, Yokoo T, Joh K, Utsunomiya Y, Hanaoka K, Hosoya T. Okonogi H, et al. Case Rep Nephrol Urol. 2012 Jan;2(1):53-8. doi: 10.1159/000339401. Epub 2012 Jun 5. Case Rep Nephrol Urol. 2012. PMID: 23197956 Free PMC article.

• Ongoing impacts of childhood-onset glomerular diseases during young adulthood.

  Furuie K, Kuraoka S, Ban H, Hidaka Y, Nagata H, Tamura H, Nagano K, Kawano T, Furuse A, Nakazato H, Nakamura K. Furuie K, et al. Pediatr Nephrol. 2024 Jun;39(6):1791-1799. doi: 10.1007/s00467-023-06250-z. Epub 2023 Dec 19. Pediatr Nephrol. 2024. PMID: 38110662 Free PMC article.

• Treatment strategy with multidrug therapy and tonsillectomy pulse therapy for childhood-onset severe IgA nephropathy.

  Kawasaki Y. Kawasaki Y. Clin Exp Nephrol. 2022 Jun;26(6):501-511. doi: 10.1007/s10157-022-02187-z. Epub 2022 Feb 4. Clin Exp Nephrol. 2022. PMID: 35119558 Review.

• Idiopathic immunoglobulin A nephropathy in children and adolescents.

  Hogg RJ. Hogg RJ. Pediatr Nephrol. 2010 May;25(5):823-9. doi: 10.1007/s00467-008-1096-3. Epub 2009 Feb 5. Pediatr Nephrol. 2010. PMID: 19194728 Free PMC article. Review.

• Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT.

  Shima Y, Nakanishi K, Kaku Y, Ishikura K, Hataya H, Matsuyama T, Honda M, Sako M, Nozu K, Tanaka R, Iijima K, Yoshikawa N; Japanese Pediatric IgA Nephropathy Treatment Study Group. Shima Y, et al. Pediatr Nephrol. 2018 Nov;33(11):2103-2112. doi: 10.1007/s00467-018-4011-6. Epub 2018 Jul 9. Pediatr Nephrol. 2018. PMID: 29987456 Clinical Trial.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal